 |
|
Mayo Clinic reports breakthrough treatment for breast cancer
October 20, 2005Concurrent NCCTG and NSABP studies find trastuzumab best for women with HER2
JACKSONVILLE, Fla. - In a joint paper, co-authored by Mayo Clinic's Edith Perez, M.D., and Edward Romond, M.D., of the National Surgical Adjuvant Breast and Bowel Project (NSABP), researchers report complete and combined results of two trials comparing adjuvant chemotherapy with or without concurrent trastuzumab treatment in women with surgically removed HER2-positive breast cancer. The studies showed trastuzumab (Herceptin®) therapy to be highly superior to standard treatment, reducing recurrence of cancer by half. The findings will be published in the Oct. 20, 2005, issue of The New England Journal of Medicine.
"Herceptin has changed the treatment of breast cancer," says Dr. Perez, who is the co-director of Mayo Clinic's Multidisciplinary Breast Clinic in Jacksonville, Fla. "When we started this study, I knew in my heart results would be positive, but this by far exceeded my expectations."
Of the 2,043 patients enrolled in NSABP trial B-31 and 1,633 patients enrolled in the two reported treatment groups of the North Central Cancer Treatment Group (NCCTG ) trial N9831 by the end of 2004, complete follow-up information was available on 3,351 patients. Two hundred sixty-one women in the control group (1,679 patients) had a recurrence of breast or other primary cancer as compared to 133 in the group receiving trastuzumab. At three years, 90.4 percent of women receiving trastuzumab were disease free, compared to 81.5 percent of women in the control group. There also was a measurable reduction in the development of other non-breast primary cancers in the B-31 trial for women receiving trastuzumab. Overall survival also appeared to be impacted, with only 62 deaths in the trastuzumab group as compared with 92 in the control group.
Dr. Perez and her co-investigators found convincing evidence that women with HER2-positive breast cancer can now be treated more effectively. "A million women each year are diagnosed with breast cancer throughout the world, and approximately 25 percent of them have HER2 tumors," said Dr. Perez. "To be able to find a treatment that impacts the lives of so many is a huge success for the cancer research community."
The NCCTG trial N9831, of which Dr. Perez was the primary investigator, was a cooperative effort with the Eastern Cooperative Oncology Group (ECOG), the Southwest Oncology Group (SWOG), and the Cancer and Leukemia Group B (CALGB). It compared three chemotherapy regimens, two that included trastuzumab therapy - one dosage concurrent with weekly paclitaxel, the other after completion of paclitaxel. The NSABP trial B-31 compared one chemotherapy regimen against the same regimen with weekly trastuzumab and tri-weekly (or weekly) paclitaxel. Investigators determined that the treatments being compared were similar, and results from the two studies were combined to form a joint analysis, excluding the NCCTG N9831 trial group that looked at trastuzumab administered sequentially after paclitaxel.
In addition to Dr. Perez, members of the NCCTG and Mayo Clinic research team included Vera Suman, Ph.D.; Thomas Pisansky, M.D.; Leila Kutteh, M.D.; Daniel Visscher, M.D.; Robert Jenkins, M.D., Ph.D.; Shaker Dakhil, M.D.; Wilma Lingle, Ph.D.; and James Ingle, M.D. Other collaborating researchers on N9831 included Nancy Davidson, M.D. (ECOG); Silvana Martino, D.O. (SWOG); and Peter Kaufman, M.D. (CALGB).
Mayo Clinic
Dr. Perez and her co-investigators found convincing evidence that women with HER2-positive breast cancer can now be treated more effectively. "A million women each year are diagnosed with breast cancer throughout the world, and approximately 25 percent of them have HER2 tumors," said Dr. Perez. "To be able to find a treatment that impacts the lives of so many is a huge success for the cancer research community."
The NCCTG trial N9831, of which Dr. Perez was the primary investigator, was a cooperative effort with the Eastern Cooperative Oncology Group (ECOG), the Southwest Oncology Group (SWOG), and the Cancer and Leukemia Group B (CALGB). It compared three chemotherapy regimens, two that included trastuzumab therapy - one dosage concurrent with weekly paclitaxel, the other after completion of paclitaxel. The NSABP trial B-31 compared one chemotherapy regimen against the same regimen with weekly trastuzumab and tri-weekly (or weekly) paclitaxel. Investigators determined that the treatments being compared were similar, and results from the two studies were combined to form a joint analysis, excluding the NCCTG N9831 trial group that looked at trastuzumab administered sequentially after paclitaxel.
In addition to Dr. Perez, members of the NCCTG and Mayo Clinic research team included Vera Suman, Ph.D.; Thomas Pisansky, M.D.; Leila Kutteh, M.D.; Daniel Visscher, M.D.; Robert Jenkins, M.D., Ph.D.; Shaker Dakhil, M.D.; Wilma Lingle, Ph.D.; and James Ingle, M.D. Other collaborating researchers on N9831 included Nancy Davidson, M.D. (ECOG); Silvana Martino, D.O. (SWOG); and Peter Kaufman, M.D. (CALGB).
Mayo Clinic
Breast Cancer Treatment Current Events and Breast Cancer Treatment News RSSPenn studies point to strategies for reducing painful breast cancer drug side effects
Aromatase inhibitors, the same drugs that have buoyed long-term survival rates among breast cancer patients, also carry side effects including joint pain so severe that many patients discontinue these lifesaving medicines.
Study shows PET can measure effectiveness of novel breast cancer treatment
A new study published in the July issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET) scans in mice can be used to determine whether a novel type of breast cancer treatment is working as intended.
Many breast cancer patients take high doses of antioxidants despite possible consequences
A new study finds that many women with breast cancer take antioxidant supplements while undergoing cancer treatment, even though the consequences of doing so are unknown.
Many breast cancer patients take high doses of antioxidants despite possible consequences
A new study finds that many women with breast cancer take antioxidant supplements while undergoing cancer treatment, even though the consequences of doing so are unknown.
Women 10 times more likely to do breast self-exams correctly with intervention, KP study finds
A brief intervention program - consisting of one counseling session and two follow-up phone calls - boosted by tenfold the number of women correctly performing breast self- exams.
High blood pressure linked to earlier death among African-American breast cancer patients
A study by researchers at the University of California, San Francisco has shown that hypertension, or high blood pressure, is a predictor of mortality among breast cancer patients, especially those who are African-American, and that hypertension accounts for approximately 30 percent of the survival disparity between African-American and white breast cancer patients.
New genomic test can personalize breast cancer treatment
A set of 50 genes can be used to reliably identify the four known types of breast cancer, according to research conducted at Washington University School of Medicine in St. Louis and collaborating institutions.
Progress made in understanding causes and treatment of endometriosis
Endometriosis is a poorly understood chronic disease characterized by infertility and chronic pelvic pain during intercourse. It affects between 5 to 10 million women in the U.S.
Obesity Increases Lymphedema Risk for Breast Cancer Survivors
Throughout the world, 10 million breast cancer survivors have a lifetime risk for developing lymphedema, a chronic condition that involves swelling of the limbs and impacts physical and psychosocial health.
Breast cancer treatment offers better outcome to women with implants
Women with early-stage breast cancer who have undergone breast augmentation may be treated successfully with a partial-breast radiation treatment called brachytherapy, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
More Breast Cancer Treatment Current Events and Breast Cancer Treatment News Articles
 |
Choices in Breast Cancer Treatment: Medical Specialists and Cancer Survivors Tell You What You Need to Know (A Johns Hopkins Press Health Book) by Kenneth D. Miller MD (Editor) A diagnosis of breast cancer can be overwhelming. The disease is frightening and the medical landscape confusing. In the wake of fear and confusion comes the need to make decisions about treatment. This book provides women with medically reliable and up-to-date information to help them with these decisions. Within these pages is a team of private consultants -- including surgeons, medical oncologists, radiologists, plastic surgeons, and women who have faced breast cancer -- each of whom offers sound advice and valuable insight. In addition to describing surgery, radiation, chemotherapy, hormone therapy, and breast reconstruction, the medical experts clarify choices and offer support, while breast cancer survivors tell their own stories of pain, perseverance, and triumph.... |
 |
My Pink Ribbon Book A Breast Cancer Treatment Journal and Organizer for BODY. MIND. SPIRIT by Vera Bradley This journal was lovingly created to be a companion for your journey. Not only a useful tool, it's a helpmate and confidante, and can assist you in making sense of everything as you chart your own course toward recovery. Also makes a thoughful gift for that special person! Measures 8" X 9" |
 |
New Treatments for Breast Cancer Breast cancer is becoming a greater threat to women's health, but there are new treatments emerging that will help women with the battle, including tumor vaccines and therapies which enhance immune response to cancer. This program focuses on the newest treatments emerging from research and for which patients they will be most appropriate. Ellie Guardino, M.D., PhD., is an Instructor in the Department of Medical Oncology at Stanford University School of Medicine. Dr. Guardino earned her MD/PhD in Microbiology and Immunology from Georgetown University. Following her residency in Internal Medicine at Harvard, she completed a fellowship in the Department of Medicine, Division of Oncology, at Stanford. Dr. Guardino is developing immune therapies and vaccines for breast cancer including... |
|
Options in the Treatment of Breast Cancer [VHS] Starring: B. Elliot Grysen M.D. J.D. Directed By: B. Elliot Grysen M.D. J.D. Also With: B. Elliot Grysen M.D. J.D. (Primary Contributor) This video production is based on the counseling sessions used by Dr. Mark Campbell to explain to his patients what breast cancer treatment options are available. These sessions have been widely acclaimed by patients and cancer support groups and now have been recorded and edited to present the same information to other patients and their families. | |
 |
12 PINK RIBBON Rubber Ducks/BREAST CANCER AWARENESS/Duckies/FUND RAISING/Inspiration by Oriental Trading Co This set of 12 pink rubber duckys are great favors for breast cancer research fund raisers. Each ducky measures approx. 2"W x 2"H x 2-1/4"L. They do not squeak but do have a hole in their beak for squirting water. They are not guaranteed to float upright. |
 |
What Cancer Cannot Do Ring (SIZE 8) Top Quality Stainless Steel! This Cancer Survivor Ring is the perfect "Pink Ribbon" Inspirational Gift for a cancer survivor or someone fighting cancer! Promote Cancer Awareness! #1 Inspirational Jewelry for Breast Cancer! Terrific Birthday Present, Holiday or Christmas Gift or Stocking Stuffer!! (See other Sizes Amazon Search: RUSH INDUSTRIES) by Rush Industries "What Cancer Cannot Do: corrode faith, shatter hope, destroy peace, silence courage, invade the soul, steel eternal life, conquer the spirit, cripple love, kill friendship, suppress memories." This hand-crafted high quality stainless steel polished hand painted enamel piece conveys a beautiful message that makes a touching gift to a friend or loved one battling cancer. Hypo allergenic! |
|
OPI Pink Of Hearts Nail Lacquer - Breast Cancer Awareness by OPI Support The Power of Pink... OPI Pink of Hearts. OPI's Exclusive Nail Lacquer For Breast Cancer Awareness Month. Show your support of Breast Cancer Awareness Month and give your customers the chance to show theirs - with Pink of Hearts, a new OPI Nail Lacquer created exclusively to support Susan G. Komen for the Cure in its promise to end breast cancer forever. In 2007 OPI will make a donation of $25,000 to Susan G. Komen for the Cure. A heartfelt, hopeful light pink, Pink of Hearts is a shade every woman will be proud to wear because it represents the power of caring, the power of women supporting each other, and the power of pink. | |
 |
Cancer Be Gone Guided imagery CD taps into the immense power of the mind to enhance comfort, healing, an optimistic attitude and positive expectations. Metaphor of "cancer as weeds in a garden that are easily managed". |
 |
Breast Cancer Homeopathic Get Well Gift Basket by Well Baskets Our Breast Cancer Get Well Basket makes a caring, empowering gift for someone just diagnosed with or already battling breast cancer. This special basket is based on the same careful research as our Cancer Patient Baskets, but is specifically targeted for individuals with breast cancer. A balanced diet rich in vitamins (including A, C, and E), minerals (Selenium), phytochemicals (such as Indoles, Perillyl Alcohol, Terpenoids, Lycopene, and Limonoids), and fiber is crucial in combating breast cancer. We've selected some of the tastiest foods containing these cancer-fighters and gathered them in this unique gift basket to aid your special woman in her fight against breast cancer. The Breast Cancer Get Well Basket Includes: Organic Green Decaf Tea Organic Honey Sensible Foods Tropical... |
 |
Fighting Breast Cancer - A Personal Story Starring: Sue Stretar Directed By: Dennis Stretar Also With: Sue Stretar (Writer), Dennis Stretar (Producer) |
| © 2009 BrightSurf.com |